{
    "id": 920,
    "fullName": "CTNNB1 S45del",
    "impact": "deletion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CTNNB1 S45del results in the deletion of an amino acid at a Gsk3b phosphorylation site of the Ctnnb1 protein at amino acid 45 (PMID: 9065402). S45del confers a gain of function to the Ctnnb1 protein as demonstrated by stabilization and nuclear accumulation of Ctnnb1 (PMID: 9065402, PMID: 21084400).",
            "references": [
                {
                    "id": 415,
                    "pubMedId": 9065402,
                    "title": "Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9065402"
                },
                {
                    "id": 2649,
                    "pubMedId": 21084400,
                    "title": "Wnt/\u03b2-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21084400"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1499,
        "geneSymbol": "CTNNB1",
        "terms": [
            "CTNNB1",
            "armadillo",
            "CTNNB",
            "EVR7",
            "MRD19",
            "NEDSDV"
        ]
    },
    "variant": "S45del",
    "createDate": "07/10/2014",
    "updateDate": "05/05/2015",
    "referenceTranscriptCoordinates": {
        "id": 138130,
        "transcript": "NM_001098210",
        "gDna": "chr3:g.41224645_41224647delTCT",
        "cDna": "c.133_135delTCT",
        "protein": "p.S45delS",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13836,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 1001,
                "profileName": "CTNNB1 S45del"
            },
            "therapy": {
                "id": 3451,
                "therapyName": "Mps-BAY2b",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 1001,
                "profileName": "CTNNB1 S45del"
            },
            "therapy": {
                "id": 3424,
                "therapyName": "Mps1-IN-1",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13832,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1 or an isogenic cell line lacking the CTNNB1 mutation, in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 1001,
                "profileName": "CTNNB1 S45del"
            },
            "therapy": {
                "id": 3461,
                "therapyName": "NTRC 0066-0",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13861,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 1001,
                "profileName": "CTNNB1 S45del"
            },
            "therapy": {
                "id": 3458,
                "therapyName": "MPI-0479605",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13844,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 1001,
                "profileName": "CTNNB1 S45del"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13853,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 1001,
                "profileName": "CTNNB1 S45del"
            },
            "therapy": {
                "id": 3446,
                "therapyName": "BAY1217389",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13847,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 1001,
                "profileName": "CTNNB1 S45del"
            },
            "therapy": {
                "id": 3445,
                "therapyName": "BAY1161909",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13848,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 1001,
                "profileName": "CTNNB1 S45del"
            },
            "therapy": {
                "id": 3445,
                "therapyName": "BAY1161909",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1001,
            "profileName": "CTNNB1 S45del",
            "profileTreatmentApproaches": [
                {
                    "id": 7940,
                    "name": "CTNNB1 Inhibitor",
                    "profileName": "CTNNB1 S45del"
                },
                {
                    "id": 7941,
                    "name": "Tankyrase Inhibitor",
                    "profileName": "CTNNB1 S45del"
                },
                {
                    "id": 7942,
                    "name": "PDPK1 Inhibitor",
                    "profileName": "CTNNB1 S45del"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 138129,
            "transcript": "NM_001098209",
            "gDna": "chr3:g.41224645_41224647delTCT",
            "cDna": "c.133_135delTCT",
            "protein": "p.S45delS",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138131,
            "transcript": "XM_006712985",
            "gDna": "chr3:g.41224645_41224647delTCT",
            "cDna": "c.133_135delTCT",
            "protein": "p.S45delS",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138135,
            "transcript": "XM_006712984",
            "gDna": "chr3:g.41224666_41224668delCCT",
            "cDna": "c.133_135delCCT",
            "protein": "p.P45delP",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138134,
            "transcript": "XM_006712983",
            "gDna": "chr3:g.41224666_41224668delCCT",
            "cDna": "c.133_135delCCT",
            "protein": "p.P45delP",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138132,
            "transcript": "XM_005264886",
            "gDna": "chr3:g.41224645_41224647delTCT",
            "cDna": "c.133_135delTCT",
            "protein": "p.S45delS",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138133,
            "transcript": "XM_017005738",
            "gDna": "chr3:g.41224645_41224647delTCT",
            "cDna": "c.133_135delTCT",
            "protein": "p.S45delS",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138128,
            "transcript": "NM_001904",
            "gDna": "chr3:g.41224645_41224647delTCT",
            "cDna": "c.133_135delTCT",
            "protein": "p.S45delS",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138130,
            "transcript": "NM_001098210",
            "gDna": "chr3:g.41224645_41224647delTCT",
            "cDna": "c.133_135delTCT",
            "protein": "p.S45delS",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}